drugset / Trial / NCT06521931
A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients
NaSingle-groupOpen-labelPrevention
Summary
The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with chemotherapy-induced thrombocytopenia (CID). The main questions it aims to answer are: * Is PN20 safe in these patients? * Could these patients potentially benefit from PN20 prevention? Participants will * Receive subcutaneous injections of PN20 according to weight on the first day of chemotherapy cycle, within 1 hour before the administration of chemotherapy drugs, * Visit the clinic on Day 1 (D1), D2, D3, D4, D5, D8, D11, D13, D15 and D21 for assessment.
Timeline
- Start
- 2023-12-06
- Primary completion
- 2025-01-13
- Completion
- 2025-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PN20 | Peptide | 0.2 mg/kg | Subcutaneous |
| Subject | PN20 | Peptide | 0.5 mg/kg | Subcutaneous |
| Subject | PN20 | Peptide | 0.75 mg/kg | Subcutaneous |